Tailoring Bruton Tyrosine Kinase Inhibitor Strategies for CLL: Managing Today, Anticipating Tomorrow
Listen now
Description
Are you selecting the right Bruton tyrosine kinase (BTK) inhibitor for your patients with chronic lymphocytic leukemia (CLL)? Experts discuss the key differentiators and upcoming developments in the field.
Credit available for this activity expires: 04/26/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000717?ecd=bdc_podcast_libsyn_mscpedu
More Episodes
What impact can weight loss have on the lives of your patients living with obesity? What treatment options are available to help you help them?
Credit available for this activity expires: 06/28/25
Earn Credit / Learning Objectives & Disclosures:...
Published 06/28/24
Published 06/28/24
The expanding world of glucagon-like peptide-1 (GLP-1) receptor antagonism. What do these developments mean for clinical practice?
Credit available for this activity expires: 6/27/25
Earn Credit / Learning Objectives & Disclosures:...
Published 06/27/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
